Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference
Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)
Outcome of Innate Pharma’s 2026 Annual General Meeting
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Number of shares and voting rights of Innate Pharma as of April 16, 2026
Innate Pharma announces conference call and webcast for Q1 2026 Business Update
Innate Pharma to participate in the D. Boral Capital Global Conference
Innate Pharma to present MATISSE Phase 2 interim results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Innate Pharma to hold its annual general meeting of shareholders on May 21, 2026
